All Blogs

Sep 25, 2018

The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...

Sep 21, 2018

Cancer treatment methodologies are always evolving, and there cannot be any denying to the fact. In this uninterrupted pursuit, old formulas are sometimes used in new ways, arousing hopes for patients as well as commercial treatment providers. A case in point is the usage of light, which has long been used to see ca...

Sep 20, 2018

Epic Sciences garners USD 52 Million for blood tests in cancer patients Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour cells while characterizing the immune response of the body at the same time. The Cancer...

Sep 19, 2018

Novo Nordisk set to restructure R&D business Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&D business, which include lay-off 400 workers of operations in Denmark and China. It is done so that the expansion is accelerated and its pipeline across serious chronic diseases is diversi...

Sep 18, 2018

A biosimilar (copycat version) is a pharmaceutical product that is close, but not identical, copy of an approved biologic branded product. It is known as a biosimilar, rather than a biogeneric, because current technology does not approve of making an exact copy of a large molecule drug and the sky reaching cost of p...

Sep 18, 2018

Argenx gets green cue in phase 2 in primary immune thrombocytopenia The Belgian biotech, Argenx has cleared phase 2 data on efgartigimod in primary immune thrombocytopenia (ITP). The results that they received, indicate at the effectiveness of the antibody Fc fragment in patients with the autoimmune bleeding disord...

Sep 14, 2018

In the grueling quest for discovering more effective cancer treatment therapies, researchers every now and then come up with interesting breakthroughs, which flash rays of hope not only to the patients, but also for the drug manufacturers to capitalize upon the discoveries. A research team, at the Houston University...

Sep 13, 2018

Atreca secured USD 125 Million when solid tumor trial comes into picture California based company, Atreca has bagged USD 125 million to establish its R&D activities. As the company gears up, the series C round enters, to move its lead solid tumor drug into the clinic.  Atreca has set up its credentials through V...

Sep 12, 2018

Aimovig of Amgen commence robust for migraine treatment The U.S. Food and Drug Administration (FDA) has given the approval to preventative migraine treatment, Aimovig of Amgen. Aimovig has a price of USD 6,900 per year, but according to analysis of sales, it gives information that migraine treatment is making its wa...

Sep 11, 2018

Nucala of GlaxoSmithKline exhibits splendid benefits to other IL-5 Inhibitors in Asthma, however flunks as a COPD Drug A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala, which targets the IL-5 pathway, was initially appro...